Evidence map›Paper›PMID 41504429›Full record

Trial reportHuman vaccines & immunotherapeutics2026

Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.

Maxime Visser, Debbie M van Rooijen, Janine Wolf, Lisa Beckers, Marien I de Jonge, Annemarie Buisman, Gerco den Hartog

Abstract readClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maxime VisserCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.ORCID 0009-0009-9780-1325
Debbie M van RooijenCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Janine WolfCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Lisa BeckersCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Marien I de JongeLaboratory of Medical Immunology, Radboud University Medical Center, Nijmegen, The Netherlands.
Annemarie BuismanCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Gerco den HartogCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carriage of

Indexed as

Antibodies, BacterialImmunoglobulin AImmunoglobulin GMeningococcal InfectionsMeningococcal VaccinesSalivaAgedAged, 80 and overFemaleHumansImmunity, MucosalImmunization, SecondaryMaleNeisseria meningitidisVaccinationVaccines, ConjugateAntibodies, BacterialImmunoglobulin AImmunoglobulin GMenACWYMeningococcal VaccinesVaccines, Conjugateantibodiesbooster vaccinationconjugate vaccinesIgAIgGMenACWY-TTmucosal responsesolder adultsprimary vaccinationsaliva

Identifiers

PMID41504429
PMCPMC12785227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.